First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy

Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene therapy for children with hearing loss linked to GJB2 gene changes.

The post First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.